Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 years ago

SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a…

ARCPOINT INC. ANNOUNCES ACCELERATED RELEASE OF LOCK-UP SHARES TO INCREASE TRADING LIQUIDITY OF SHARES

2 years ago

Greenville, South Carolina, March 17, 2023 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV:ARC) (the “Company” or “ARCpoint”), announces accelerated release of…

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of February 28, 2023

2 years ago

Disclosure of Share Capital and Voting Rights Outstanding as of February 28, 2023 (Pursuant to Article L.233-8 II of the…

Eargo to Report Fourth Quarter 2022 Financial Results on March 23, 2023

2 years ago

SAN JOSE, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission…

Clinical Study Results Involving Spryng, a PetVivo Holdings, Inc. Product, Presented at the Veterinary Orthopedic Society Annual Conference in Big Sky, Montana

2 years ago

MINNEAPOLIS, MN, US, March 17, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo")…

Better Choice’s Halo Pet Food Brand Awarded “2022 Consumer’s Favorite Imported Cat Brand” by the China Pet Industry White Paper

2 years ago

After polling over 30,000 pet owners in China, Halo was voted as one of the top picks in the imported…

CancerVax Universal Cancer Vaccine Being Developed by UCLA

2 years ago

The UCLA research team, which includes Dr. Steven Jonas, Dr. Christopher Seet, Dr. Satiro De Oliveira and Dr. Christopher Denny,…

Healthcare Integrated Technologies, Inc. Announces Approval of U.S. Patent for Fall Validation with Privacy-Aware Monitoring System

2 years ago

Knoxville, Tennessee, March 17, 2023 (GLOBE NEWSWIRE) -- Healthcare Integrated Technologies, Inc. (“HiTC”), a leading innovator of healthcare technology solutions,…

Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting

2 years ago

Alvotech to present two posters related to pharmacokinetics and confirmatory clinical studies for AVT04 (ustekinumab), a proposed biosimilar to Stelara®…

Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting

2 years ago

Alvotech to present two posters related to pharmacokinetics and confirmatory clinical studies for AVT04 (ustekinumab), a proposed biosimilar to Stelara®Marketing…